Back to SNYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Acquired Thrombotic Thrombocytopenic Purpura
View Full LandscapeDrug Information
Target Indication
Acquired Thrombotic Thrombocytopenic Purpura
Clinical Trial
NCT02553317Last updated: 12/10/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/30/2018
Cablivi
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Insulin Glargine (Mandatory background drug)Phase 3
Type 2 Diabetes
gemcitabine/carboplatin plus IniparibPhase 3
Squamous Cell Lung Cancer
Metformin (Background drug)Phase 3
Type 2 Diabetes
Androgen Suppression Therapy and Radiation TherapyPhase 3
Prostate Cancer
LinvoseltamabPhase 3
Multiple Myeloma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
